Network meta-analysis
Weight loss of 15 percent or more
Overweight or obesity without diabetes (adults)
weeks 40 to 104 (target week 68)Not stated by the trialsEach dose separatelyOdds ratioSeparate part 2 of a disconnected network
11
Randomized trials
14
Treatments
3,569
Participants
1,113
Events
In plain language
Across 11 trials with 3,569 participants, 10 of 13 treatments had a clearly better result than placebo on weight loss of 15 percent or more, and for 3 the evidence could not tell them apart from placebo. The most favorable estimate was for Semaglutide and bimagrumab 2.4 to 30 mg injection once weekly: odds ratio 40.91 (95% credible interval 13.54 to 124).
Higher values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Odds ratio. Higher values favor the treatment.
| Treatment | Bayesian OR (95% CrI) | 95% prediction interval | Frequentist OR (95% CI) | Verdict |
|---|---|---|---|---|
| Semaglutide and bimagrumab 2.4 to 30 mg injection once weekly BIMASEMA_SC_2p4-30MG_QW | 40.91 (13.54 to 124) | 10.10 to 151 | 59.17 (19.07 to 184) | Better |
| Semaglutide 50 mg oral once daily (higher dose oral program) SEMA_PO_50MG_QD | 18.00 (6.83 to 41.71) | 5.27 to 52.83 | 18.91 (8.17 to 43.77) | Better |
| Semaglutide and bimagrumab 1.0 to 30 mg injection once weekly BIMASEMA_SC_1p0-30MG_QW | 17.23 (5.84 to 48.24) | 4.76 to 59.26 | 23.95 (8.33 to 68.87) | Better |
| Semaglutide and bimagrumab 2.4 to 10 mg injection once weekly BIMASEMA_SC_2p4-10MG_QW | 13.68 (4.65 to 37.85) | 3.57 to 45.41 | 19.14 (6.61 to 55.41) | Better |
| Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW | 13.02 (8.93 to 20.10) | 5.75 to 32.84 | 13.76 (9.02 to 20.97) | Better |
| Semaglutide and bimagrumab 1.0 to 10 mg injection once weekly BIMASEMA_SC_1p0-10MG_QW | 7.97 (2.66 to 21.42) | 2.09 to 26.70 | 11.09 (3.84 to 32.08) | Better |
| Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW | 7.91 (1.86 to 37.51) | 1.59 to 42.80 | 9.83 (1.85 to 52.17) | Better |
| Semaglutide 1.7 mg injection once weekly SEMA_SC_1p7MG_QW | 6.33 (2.62 to 15.95) | 2.03 to 20.74 | 6.96 (2.86 to 16.92) | Better |
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | 6.18 (2.10 to 16.75) | 1.53 to 20.15 | 8.64 (3.01 to 24.83) | Better |
| Bimagrumab OTHER_ACTIVE_bimagrumab | 3.80 (1.33 to 10.00) | 1.04 to 12.33 | 5.22 (1.88 to 14.50) | Better |
| Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW | 2.89 (0.67 to 14.78) | 0.56 to 16.56 | 3.70 (0.66 to 20.63) | Unclear |
| Liraglutide 3.0 mg subcutaneous once daily LIRA_SC_3p0MG_QD | 1.52 (0.62 to 3.75) | 0.47 to 5.02 | 1.60 (0.63 to 4.09) | Unclear |
| Standard care or no added treatment STANDARD_CARE | 0.30 (0.08 to 1.24) | 0.06 to 1.49 | 0.33 (0.08 to 1.38) | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: odds ratio of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | BIMASEMA_SC_2p4-30MG_QW | SEMA_PO_50MG_QD | BIMASEMA_SC_1p0-30MG_QW | BIMASEMA_SC_2p4-10MG_QW | SEMA_SC_2p4MG_QW | BIMASEMA_SC_1p0-10MG_QW | TIRZ_SC_15MG_QW | SEMA_SC_1p7MG_QW | SEMA_SC_1p0MG_QW | OTHER_ACTIVE_bimagrumab | TIRZ_SC_10MG_QW | LIRA_SC_3p0MG_QD | STANDARD_CARE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 0.02 0.01 to 0.07 | 0.06 0.02 to 0.15 | 0.06 0.02 to 0.17 | 0.07 0.03 to 0.22 | 0.08 0.05 to 0.11 | 0.13 0.05 to 0.38 | 0.13 0.03 to 0.54 | 0.16 0.06 to 0.38 | 0.16 0.06 to 0.48 | 0.26 0.10 to 0.75 | 0.35 0.07 to 1.49 | 0.66 0.27 to 1.62 | 3.30 0.81 to 12.97 |
| BIMASEMA_SC_2p4-30MG_QW | 40.91 13.54 to 124 | BIMASEMA_SC_2p4-30MG_QW | 2.30 0.55 to 9.68 | 2.42 0.73 to 7.95 | 3.04 0.95 to 10.05 | 3.13 1.03 to 9.08 | 5.23 1.60 to 17.48 | 5.21 0.73 to 31.49 | 6.62 1.57 to 24.09 | 6.71 2.11 to 21.82 | 10.96 3.53 to 33.72 | 14.00 1.92 to 88.20 | 27.50 6.39 to 101 | 137 22.82 to 712 |
| SEMA_PO_50MG_QD | 18.00 6.83 to 41.71 | 0.43 0.10 to 1.80 | SEMA_PO_50MG_QD | 1.04 0.26 to 4.03 | 1.31 0.35 to 5.10 | 1.39 0.45 to 3.49 | 2.24 0.58 to 9.17 | 2.26 0.37 to 11.61 | 2.83 0.69 to 9.60 | 2.92 0.73 to 11.18 | 4.70 1.21 to 18.18 | 6.13 0.94 to 33.57 | 11.95 2.99 to 39.43 | 59.95 10.24 to 280 |
| BIMASEMA_SC_1p0-30MG_QW | 17.23 5.84 to 48.24 | 0.41 0.13 to 1.36 | 0.96 0.25 to 3.79 | BIMASEMA_SC_1p0-30MG_QW | 1.26 0.41 to 3.90 | 1.32 0.45 to 3.50 | 2.16 0.70 to 6.86 | 2.19 0.33 to 12.63 | 2.75 0.67 to 9.15 | 2.78 0.92 to 8.54 | 4.51 1.54 to 13.50 | 5.87 0.85 to 36.25 | 11.31 2.78 to 41.89 | 56.16 9.31 to 306 |
| BIMASEMA_SC_2p4-10MG_QW | 13.68 4.65 to 37.85 | 0.33 0.10 to 1.05 | 0.76 0.20 to 2.89 | 0.79 0.26 to 2.45 | BIMASEMA_SC_2p4-10MG_QW | 1.05 0.35 to 2.68 | 1.72 0.55 to 5.33 | 1.72 0.25 to 9.96 | 2.16 0.55 to 7.50 | 2.21 0.72 to 6.84 | 3.61 1.21 to 10.48 | 4.69 0.65 to 28.67 | 9.05 2.17 to 31.63 | 45.20 7.47 to 227 |
| SEMA_SC_2p4MG_QW | 13.02 8.93 to 20.10 | 0.32 0.11 to 0.97 | 0.72 0.29 to 2.20 | 0.76 0.29 to 2.23 | 0.95 0.37 to 2.87 | SEMA_SC_2p4MG_QW | 1.64 0.63 to 4.96 | 1.66 0.34 to 7.34 | 2.06 0.89 to 4.85 | 2.11 0.82 to 6.15 | 3.42 1.39 to 9.76 | 4.54 0.85 to 21.20 | 8.59 3.60 to 20.97 | 42.90 11.14 to 167 |
| BIMASEMA_SC_1p0-10MG_QW | 7.97 2.66 to 21.42 | 0.19 0.06 to 0.63 | 0.45 0.11 to 1.71 | 0.46 0.15 to 1.43 | 0.58 0.19 to 1.83 | 0.61 0.20 to 1.59 | BIMASEMA_SC_1p0-10MG_QW | 0.99 0.15 to 5.63 | 1.26 0.31 to 4.29 | 1.28 0.43 to 3.92 | 2.09 0.70 to 6.08 | 2.69 0.38 to 16.47 | 5.24 1.25 to 18.68 | 26.14 4.52 to 137 |
| TIRZ_SC_15MG_QW | 7.91 1.86 to 37.51 | 0.19 0.03 to 1.36 | 0.44 0.09 to 2.72 | 0.46 0.08 to 3.04 | 0.58 0.10 to 3.96 | 0.60 0.14 to 2.92 | 1.01 0.18 to 6.82 | TIRZ_SC_15MG_QW | 1.24 0.22 to 7.78 | 1.29 0.22 to 8.41 | 2.08 0.39 to 12.84 | 2.70 0.82 to 8.99 | 5.21 0.93 to 31.61 | 26.34 3.31 to 208 |
| SEMA_SC_1p7MG_QW | 6.33 2.62 to 15.95 | 0.15 0.04 to 0.64 | 0.35 0.10 to 1.45 | 0.36 0.11 to 1.49 | 0.46 0.13 to 1.83 | 0.48 0.21 to 1.13 | 0.79 0.23 to 3.22 | 0.81 0.13 to 4.50 | SEMA_SC_1p7MG_QW | 1.02 0.29 to 4.00 | 1.66 0.51 to 6.60 | 2.20 0.34 to 12.50 | 4.15 1.29 to 14.06 | 20.51 4.17 to 103 |
| SEMA_SC_1p0MG_QW | 6.18 2.10 to 16.75 | 0.15 0.05 to 0.47 | 0.34 0.09 to 1.36 | 0.36 0.12 to 1.09 | 0.45 0.15 to 1.39 | 0.47 0.16 to 1.22 | 0.78 0.26 to 2.35 | 0.78 0.12 to 4.45 | 0.98 0.25 to 3.40 | SEMA_SC_1p0MG_QW | 1.63 0.55 to 4.79 | 2.09 0.31 to 13.00 | 4.06 1.04 to 14.39 | 20.28 3.55 to 105 |
| OTHER_ACTIVE_bimagrumab | 3.80 1.33 to 10.00 | 0.09 0.03 to 0.28 | 0.21 0.05 to 0.82 | 0.22 0.07 to 0.65 | 0.28 0.10 to 0.83 | 0.29 0.10 to 0.72 | 0.48 0.16 to 1.42 | 0.48 0.08 to 2.55 | 0.60 0.15 to 1.96 | 0.62 0.21 to 1.83 | OTHER_ACTIVE_bimagrumab | 1.30 0.19 to 7.33 | 2.53 0.67 to 8.63 | 12.54 2.31 to 63.04 |
| TIRZ_SC_10MG_QW | 2.89 0.67 to 14.78 | 0.07 0.01 to 0.52 | 0.16 0.03 to 1.07 | 0.17 0.03 to 1.18 | 0.21 0.03 to 1.55 | 0.22 0.05 to 1.17 | 0.37 0.06 to 2.61 | 0.37 0.11 to 1.22 | 0.45 0.08 to 2.92 | 0.48 0.08 to 3.25 | 0.77 0.14 to 5.27 | TIRZ_SC_10MG_QW | 1.93 0.33 to 12.17 | 9.70 1.24 to 76.30 |
| LIRA_SC_3p0MG_QD | 1.52 0.62 to 3.75 | 0.04 0.01 to 0.16 | 0.08 0.03 to 0.33 | 0.09 0.02 to 0.36 | 0.11 0.03 to 0.46 | 0.12 0.05 to 0.28 | 0.19 0.05 to 0.80 | 0.19 0.03 to 1.08 | 0.24 0.07 to 0.78 | 0.25 0.07 to 0.96 | 0.40 0.12 to 1.49 | 0.52 0.08 to 3.05 | LIRA_SC_3p0MG_QD | 4.93 1.71 to 15.54 |
| STANDARD_CARE | 0.30 0.08 to 1.24 | 0.01 0.00 to 0.04 | 0.02 0.00 to 0.10 | 0.02 0.00 to 0.11 | 0.02 0.00 to 0.13 | 0.02 0.01 to 0.09 | 0.04 0.01 to 0.22 | 0.04 0.00 to 0.30 | 0.05 0.01 to 0.24 | 0.05 0.01 to 0.28 | 0.08 0.02 to 0.43 | 0.10 0.01 to 0.81 | 0.20 0.06 to 0.59 | STANDARD_CARE |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 6 of 11 | Type 2 diabetes share in weight trials (percent of participants) effect modifier; 11 of 11 | Sex (percent female) effect modifier, prognostic factor; 11 of 11 | Treatment duration (weeks) effect modifier; 11 of 11 | Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 11 of 11 |
|---|---|---|---|---|---|
| STEP 5 S000214 | 38.55 | 0 population codes | 77.6 | 104 | standard |
| BARI-STEP S000434 | 41.5 | 10 | 82.85 | 68 | standard |
| NCT05616013 S000715 | 37.3 | 0 population codes | 57.37 | 48 | standard |
| STEP 10 S000832 | 39.9 | 0 population codes | 71.01 | 52 | not_reported |
| STEP 3 S000988 | 38 | 0 population codes | 81.01 | 68 | intensive |
| SURMOUNT-CN S001086 | body weight 91.8 kg | 0 population codes | 49.05 | 52 | standard |
| STEP7 S001288 | not reported | 0 population codes | 45.33 | 44 | standard |
| OASIS 1 S001472 | not reported | 0 population codes | 72.71 | 68 | not_reported |
| STEP 8 S001600 | not reported | 0 population codes | 78.4 | 68 | standard |
| STRIVE S001687 | 45.96 | 35.5 | 64.28 | 104 | intensive |
| STEP 6 S002102 | not reported | 0 population codes | 36.91 | 68 | not_reported |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Baseline BMI or body weight: not reported by 5 of 11 trials
- FlagBaseline, Baseline BMI or body weight: design means range from 37.3 (BIMASEMA_SC_1p0-10MG_QW vs BIMASEMA_SC_1p0-30MG_QW vs BIMASEMA_SC_2p4-10MG_QW vs BIMASEMA_SC_2p4-30MG_QW vs OTHER_ACTIVE_bimagrumab vs PLACEBO vs SEMA_SC_1p0MG_QW vs SEMA_SC_2p4MG_QW) to 46.0 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) kg/m2; threshold 3
- FlagBaseline, Type 2 diabetes share in weight trials: design means range from 0.0 (BIMASEMA_SC_1p0-10MG_QW vs BIMASEMA_SC_1p0-30MG_QW vs BIMASEMA_SC_2p4-10MG_QW vs BIMASEMA_SC_2p4-30MG_QW vs OTHER_ACTIVE_bimagrumab vs PLACEBO vs SEMA_SC_1p0MG_QW vs SEMA_SC_2p4MG_QW) to 35.5 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) percent of participants; threshold 20
- FlagBaseline, Sex: design means range from 36.9 (PLACEBO vs SEMA_SC_1p7MG_QW vs SEMA_SC_2p4MG_QW) to 78.4 (LIRA_SC_3p0MG_QD vs PLACEBO vs SEMA_SC_2p4MG_QW) percent female; threshold 15
- FlagBaseline, Treatment duration: design means range from 48.0 (BIMASEMA_SC_1p0-10MG_QW vs BIMASEMA_SC_1p0-30MG_QW vs BIMASEMA_SC_2p4-10MG_QW vs BIMASEMA_SC_2p4-30MG_QW vs OTHER_ACTIVE_bimagrumab vs PLACEBO vs SEMA_SC_1p0MG_QW vs SEMA_SC_2p4MG_QW) to 104.0 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) weeks; threshold 26
- NoteOutcome assessment, time point: selected time points span 44 to 78 weeks
- NoteOutcome assessment, analysis set: mixed: completers 3, full_analysis 7, modified_itt 1
- NoteOutcome assessment, proportion method: mixed: not stated 9, observed 2
- NoteRisk of bias, blinding: mixed: double_blind 9, open_label 2
- NoteRisk of bias, funding: mixed: industry 10, mixed 1
- NoteData handling, input conversions: arms_combined 1, count_from_percent 11
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEP 5 | 52 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent |
| BARI-STEP | 68 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2022 | age 18 to 65; at least 1 year after primary bypass or sleeve; less than 20 percent weight loss from surgery |
| NCT05616013 | 48 | completers | not stated | not stated | not stated | observed | not stated | not stated | open_label | industry | 2022 | adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg |
| STEP 10 | 52 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Adults with obesity and prediabetes; diabetes excluded |
| STEP 3 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2018 | BMI 30 or more, or 27 with comorbidity; no type 2 diabetes |
| SURMOUNT-CN | 78 | completers | not stated | not stated | not stated | observed | not stated | not stated | double_blind | industry | 2021 | Chinese adults; BMI 28 or more, or 24 or more with a weight related comorbidity; no diabetes |
| STEP7 | 44 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 or older; BMI 30 or more, or 27 or more with a weight related comorbidity including T2D |
| OASIS 1 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | overweight or obesity |
| STEP 8 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or higher, or 27 with a weight related comorbidity; no type 2 diabetes |
| STRIVE | 52 | completers | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2017 | age 18 to 75; BMI 35 or more plus prediabetes, T2D, hypertension or sleep apnea; no insulin or GLP-1 RA |
| STEP 6 | 68 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the odds ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| STEP 5 | A1 | SEMA_SC_2p4MG_QW | 52 | arm, responders | 78 / 149 | registry:outcomes | |||
| STEP 5 | A2 | PLACEBO | 52 | arm, responders | 7 / 129 | registry:outcomes | |||
| BARI-STEP | A1 | PLACEBO | 68 | arm, responders | 2 / 29 | R0014003:Results | |||
| BARI-STEP | A2 | SEMA_SC_2p4MG_QW | 68 | arm, responders | 21 / 34 | R0014003:Results | |||
| NCT05616013 | A1 | PLACEBO | 48 | arm, responders | 2 / 35 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A2+A3 | OTHER_ACTIVE_bimagrumab | 48 | arm, responders | 17 / 68 | count_from_percent;arms_combined | registry:outcomes | ||
| NCT05616013 | A4 | SEMA_SC_1p0MG_QW | 48 | arm, responders | 16 / 45 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A5 | SEMA_SC_2p4MG_QW | 48 | arm, responders | 24 / 51 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A6 | BIMASEMA_SC_1p0-10MG_QW | 48 | arm, responders | 17 / 41 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A7 | BIMASEMA_SC_2p4-10MG_QW | 48 | arm, responders | 22 / 40 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A8 | BIMASEMA_SC_1p0-30MG_QW | 48 | arm, responders | 26 / 43 | count_from_percent | registry:outcomes | ||
| NCT05616013 | A9 | BIMASEMA_SC_2p4-30MG_QW | 48 | arm, responders | 34 / 43 | count_from_percent | registry:outcomes | ||
| STEP 10 | A1 | SEMA_SC_2p4MG_QW | 52 | arm, responders | 62 / 129 | registry:outcomes | |||
| STEP 10 | A2 | PLACEBO | 52 | arm, responders | 1 / 66 | registry:outcomes | |||
| STEP 3 | A1 | SEMA_SC_2p4MG_QW | 68 | arm, responders | 208 / 373 | registry:outcomes | |||
| STEP 3 | A2 | PLACEBO | 68 | arm, responders | 25 / 189 | registry:outcomes | |||
| SURMOUNT-CN | A1 | TIRZ_SC_10MG_QW | 78 | arm, responders | 9 / 54 | count_from_percent | R0007857:Results | ||
| SURMOUNT-CN | A2 | TIRZ_SC_15MG_QW | 78 | arm, responders | 17 / 49 | count_from_percent | R0007857:Results | ||
| SURMOUNT-CN | A3 | PLACEBO | 78 | arm, responders | 2 / 39 | count_from_percent | R0007857:Results | ||
| STEP7 | A1 | SEMA_SC_2p4MG_QW | 44 | arm, responders | 82 / 238 | registry:outcomes | |||
| STEP7 | A2 | PLACEBO | 44 | arm, responders | 7 / 116 | registry:outcomes | |||
| OASIS 1 | A1 | SEMA_PO_50MG_QD | 68 | arm, responders | 170 / 317 | registry:outcomes | |||
| OASIS 1 | A2 | PLACEBO | 68 | arm, responders | 17 / 295 | registry:outcomes | |||
| STEP 8 | A1 | SEMA_SC_2p4MG_QW | 68 | arm, responders | 65 / 117 | registry:outcomes | |||
| STEP 8 | A2 | LIRA_SC_3p0MG_QD | 68 | arm, responders | 14 / 117 | registry:outcomes | |||
| STEP 8 | A3 | PLACEBO | 68 | arm, responders | 5 / 78 | registry:outcomes | |||
| STRIVE | A1 | STANDARD_CARE | 52 | arm, responders | 6 / 93 | R0020855:Table 2 | |||
| STRIVE | A2 | LIRA_SC_3p0MG_QD | 52 | arm, responders | 51 / 201 | R0020855:Table 2 | |||
| STEP 6 | A1 | SEMA_SC_1p7MG_QW | 68 | arm, responders | 24 / 98 | registry:outcomes | |||
| STEP 6 | A2 | SEMA_SC_2p4MG_QW | 68 | arm, responders | 79 / 193 | registry:outcomes | |||
| STEP 6 | A3 | PLACEBO | 68 | arm, responders | 3 / 100 | registry:outcomes |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.